In adults with overweight or obesity and metabolic dysfunctionassociated steatohepatitis, also known as MASH, with moderate or advanced fibrosis, the treatment plan should include a GLP-1RA or a dual GIP/GLP-1RA with demonstrated or potential benefits on MASH
Approval usually depends on provider documentation, lifestyle changes, and, sometimes, step therapy, which requires that lower-cost treatments or programs be tried first
After excluding patients with prior herpes infection and applying a new-use design, 155,793 GLP-1RA users and 138,295 DPP-4i users remained
The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included cardiovascular death, non-fatal myocardial infarction and non-fatal stroke